DHFR and RRM1 are linked with sensitivity to therapeutics used in MPM, pemetrexed, and gemcitabine, respectively; however, they did not stratify by BAP1 status (Supplementary Fig. S11B), implying more complex regulation of their expression in cancer. Here, RRM1 is linked to cancer.